Whole Body Hyperthermia and Major Depression (MDD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of Arizona
Sponsor:
Collaborators:
Dr. med. h.c. Erwin Braun Foundation
The Depressive and Bipolar Disorder Alternative Treatment Foundation
Brain & Behavior Research Foundation
Information provided by (Responsible Party):
University of Arizona
ClinicalTrials.gov Identifier:
NCT01625546
First received: June 19, 2012
Last updated: February 4, 2014
Last verified: February 2014
  Purpose

Major depressive disorder (MDD) is predicted to be the second leading cause of disability worldwide by the year 2020. The economic burden of depression in the United States is significant: $83.1 billion in 2000 and increasing. Much of this burden comes from the high rate of sub-optimal treatment outcomes associated with the disorder. Indeed, only 50% of MDD patients recover in less than 12 weeks with adequate treatment, and up to 20% of patients will fail to adequately respond to all currently available interventions. Moreover, current treatments come at the cost of significant central nervous system (CNS) side effects, further highlighting the need for more effective treatments with fewer side effects. This study will compare temperature ranges from the investigators preliminary studies involving thermoafferent pathways resulting in antidepressant actions with lower temperature ranges not expected to activate these pathways as a control condition, with the goal to evaluate whether previous observations were related to the temperature range in question or can be achieved with other levels.


Condition Intervention
Depressive Disorder, Major
Device: Whole Body Hyperthermia system

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Whole Body Hyperthermia and Major Depression (MDD)

Resource links provided by NLM:


Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • 17-item Hamilton Rating Scale for Depression (HAM-D; derived from the 31-item instrument) [ Time Frame: Screening, at intervention, and at weeks 1, 2, 4 and 6 following the intervention. Additionally, at the open treatment, 1 week following the open treatment and at the 3-month follow up. ] [ Designated as safety issue: No ]
    To determine acute and sustained effects of Whole Body Hyperthermia (WBH) on depression severity.


Secondary Outcome Measures:
  • Change in QIDS (Quick Inventory of Depressive Symptoms) Score from baseline response [ Time Frame: Screening, at intervention, and at weeks 1, 2, 4 and 6 following the intervention. Additionally, at the open treatment, 1 week following the open treatment and at the 3-month follow up. ] [ Designated as safety issue: No ]
  • Core body temperature monitoring [ Time Frame: 3 days (over the weekend) at baseline, week 1 and week 4. ] [ Designated as safety issue: No ]
    Body temperature will be measured with a Vitalsense unit (Minimitter Respironics, Bend OR). The Vitalsense system includes easy to swallow telemetric capsules about the size of a multivitamin (dimensions 23 cm x 8.7 mm) made of medical grade plastic (biocompatible polycarbonate). After ingestion, pills normally pass between 1 to 5 days (mean 2 ± 1.5 days) and then are discarded. A second pill will be ingested if the pill passes during the study visit. Pill temperature sensors transmit data to a small, battery operated, lightweight, user-worn device that may be worn on a belt or placed in a pocket (Dimensions 120 x 90 x 25 mm; weight 200 grams). The devise can collect up to 10 channels for 240 h without battery replacement or download.

  • Skin conductance level [ Time Frame: On the day of the WBH or control treatment, and at one and 4 weeks following the control/intervention. ] [ Designated as safety issue: No ]
    Thermoregulatory cooling will be assessed by 1) skin conductance level (SCL) following the protocol outlined by Ward et al

  • Heart Rate Variability [ Time Frame: On the day of the WBH or control treatment, and at one and 4 weeks following the control/intervention. ] [ Designated as safety issue: No ]
    Heart Rate Variability (HRV) will be assessed during the period of SCL collection and will be calculated using both time and frequency domain methodologies.

  • EAR Assessment [ Time Frame: 3 days (over the weekend) at baseline, week 1 and week 4. ] [ Designated as safety issue: No ]
    To assess whether WBH affects how individuals relate to other people in their environment, as well as how they spend their time in general and to assess social processes, the study will employ the Electronically Activated Recorder (EAR).

  • Sleep assessment [ Time Frame: 3 days (over the weekend) at baseline, week 1 and week 4. ] [ Designated as safety issue: No ]
    To assess how the WBH affects sleep, participants will be given an actigraph to wear on their non-dominant wrist over three days and nights during the weekend assessments at baseline, post-intervention week 1 and study week 4. They will also be instructed to complete a daily sleep diary during the time they wear the sleep watch.

  • Plasma Concentrations of Biological Predictors of Response and Mechanism of Action for WBH. [ Time Frame: Prior to WBH or control, following WBH or control, and at Week 1 and Week 4 follow-up visits. ] [ Designated as safety issue: No ]
    Blood samples will be analyzed for physiological measures expected to be impacted by WBH including RNA expression, plasma concentrations of BDNF, and pro- and anti-inflammatory cytokines.

  • QIDS = Quick Inventory of Depressive Symptoms [ Time Frame: Screening, baseline, WBH intervention day, once during the three days following the intervention, and at Week 1, 2, 4 and 6 following intervention. Additionally at the open treatment, 1 week following the open treatment and at the 3-month follow up. ] [ Designated as safety issue: No ]
    To determine effects of Whole Body Hyperthermia (WBH) on depressive symptoms.


Estimated Enrollment: 30
Study Start Date: July 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: High intensity whole-body infrared heating
Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
Device: Whole Body Hyperthermia system
The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
Sham Comparator: Low intensity whole-body infrared heating
Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
Device: Whole Body Hyperthermia system
The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.

Detailed Description:

We will conduct a placebo controlled clinical trial to determine if Whole Body Hyperthermia has antidepressant effects in medically healthy patients with moderate to severe MDD. We plan to recruit a sample of 30 medically healthy individuals with MDD who will be randomized to examine whether WBH will demonstrate an antidepressant effect when compared to a control-WBH condition that will be comprised of very mild heating in the WBH machine (Heckel HT3000). To determine acute and sustained effects of WBH on depression severity, the study will include basic clinical and psychiatric assessments 5 days before and after WBH and follow-up assessments at 2, 4, and 6 weeks following WBH. Additionally, assessments will be conducted during the optional open treatment, 1 week following the open treatment, and at the 3 month follow up. To assess whether WBH affects how individuals relate to other people in their environment, as well as how they spend their time in general and to assess social processes, the study will employ the Electronically Activated Recorder (EAR). Participants will wear the EAR device during the day, while going about their lives over the weekend. This weekend monitoring also includes an actigraphy assessment during which participants will wear an actigraphy device during their waking and sleeping hours. In addition, blood will be obtained at multiple time points to assess plasma concentrations of biological predictors or response and mechanism of action for WBH. This study challenges the existing paradigm by determining if peripheral afferent sensory pathways can be accessed to treat MDD and thus avoid problems of exposing all of the brain to non-selective drugs.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for MDD patients:

  1. Male or female outpatients aged 18-65.
  2. Able to understand the nature of the study and able to provide written informed consent prior to conduct of any study procedures.
  3. In the investigator's opinion, has met DSM-IV-TR criteria for Major Depressive Disorder for at least 4 weeks prior to signing consent, single or recurrent episode, without psychotic features, as the subject's primary psychiatric disorder.
  4. Able to communicate in English with study personnel.
  5. Has a Hamilton Depression Rating Scale (HDRS) score ≥18 at screening and ≥14 on intervention day.
  6. For women of child-bearing potential (i.e., one who is biologically capable of becoming pregnant), must be willing to use a medically acceptable form of birth control or practice abstinence for the duration of her participation in the trial.

Exclusion Criteria for MDD patients:

  1. Symptoms of depression which, in the investigator's opinion, are better accounted for by a diagnosis other than Major Depressive Disorder.
  2. Any of the following diagnoses, as identified by the psychiatric evaluation or study assessments:

    • A current DSM-IV-TR Axis I diagnosis of Dementia; or
    • Any current DSM-IV-TR Axis II diagnosis (i.e. personality disorder) that would suggest potential noncompliance with the protocol; or
    • A lifetime history of Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder Type 1; or
    • A diagnosis claustrophobia severe enough that it would impair ability to be in the Heckel HT3000 hyperthermia device
    • A current (or within 12 months prior to the Screening visit) diagnosis of Anorexia Nervosa or Bulimia Nervosa
  3. Subject has met DSM-IV criteria for Substance Abuse in the 3 months prior to screening visit, or non-remitted Substance Dependence in the 6 months prior to screening visit.
  4. A diagnosis of an anxiety disorder that is considered by the investigator to be of greater source of distress or functional impairment than the patient's depressive symptoms. Subjects with comorbid anxiety disorders not excluded above and considered to be of secondary importance will be permitted in the study.
  5. Participation in concurrent formal psychotherapy during the trial, or in the 2 weeks prior to the screening visit.
  6. Individuals with a history of having difficulty swallowing food or large capsules will be excluded from participating in the assessment of core body temperature (because swallowing a large sensor pill is required). The ingestible temperature capsules will not be used in subjects with any known or suspected obstructive disease of the gastrointestinal tract including, but not limited to esophageal stricture, diverticulosis and inflammatory bowel disease (IBD), peptic ulcer disease, Crohn's disease, ulcerative colitis; previous gastrointestinal surgery.
  7. Subject has a medical condition or disorder that:

    • Is unstable and clinically significant, or:
    • Could interfere with the accurate assessment of safety or efficacy of treatment, including:

      1. individuals who are using prescription drugs that may impair thermoregulatory cooling, including diuretics, barbiturates, and beta-blockers, or antihistamines,
      2. individuals with cardiovascular conditions or problems (uncontrolled hypertension, congestive heart failure, or documented evidence of coronary artery disease)
      3. individuals with chronic conditions/diseases associated with a reduced ability initiate thermoregulatory cooling, including Parkinson's, multiple sclerosis, central nervous system tumors, and diabetes with neuropathy,
      4. hemophiliacs/individuals prone to bleeding,
      5. individuals with a fever the day of study intervention,
      6. individuals with hypersensitivity to heat,
      7. individuals with recent acute joint injury,
      8. individuals with enclosed infections, be they dental, in joints, or in any other tissues,
      9. individuals with silicone implants; silicone does absorb far infrared energy. Implanted silicone or silicone prostheses for nose or ear replacement may be warmed by the far infrared waves. Since silicone melts at over 200°C (392°F), it should not be adversely affected by the usage of an infrared heating. Nevertheless, the effects of infrared heating on all silicone composites used in implants are not known, and therefore individuals with silicone implants will be excluded from this study.
      10. Individuals with saline implants
  8. Clinically significant, in the investigator's opinion, abnormal findings on screening laboratory tests or physical exam.
  9. Presence of clinically significant suicide risk, based on the investigator's opinion, or a Columbia Suicide Severity Risk Scale (C-SSRS) suicidal ideation score of 4 or 5. Any suicide attempt within 3 months of the Screening visit is exclusionary.
  10. Use of any psychotropic medications for 2 weeks (8 weeks for fluoxetine) prior to initiation of the study, with the exception of hypnotic medications (zolpidem, zaleplon, eszopiclone).
  11. Need for any non-protocol psychotropic medication during the trial, with the exception of hypnotics used up to four nights per week.
  12. Use of any psychoactive dietary or herbal products in the 2 weeks prior to screening visit 2, or at any time during the trial.
  13. Women who are pregnant (HCG pregnancy test at screening, or lactating, or who plan to become pregnant during the study.
  14. Current participation in any clinical trial that might impact results of this one, which includes participation in another clinical trial for depression, as well as drug trials with agents that might affect mood or regulation of body temperature.
  15. Reasonable likelihood for non-compliance with the protocol for any other reason, in the opinion of the Investigator, prohibits enrollment of subject into the study.
  16. Obesity and overall size of subject. It will be up to the PI's discretion will consider BMI, waist circumference, and body fat composition when determining eligibility and safety of the individual.
  17. History of peripheral circulatory disease, for example peripheral vascular disease, deep vein thrombosis (DVT), or lymphedema.
  18. History of a cerebral vascular accident
  19. History of stroke, epilepsy or cerebral aneurisms
  20. Cancer in the last five years.
  21. Diabetes mellitus types I or II
  22. Any clinically significant autoimmune disease (compensated hypothyroidism allowed)
  23. Active alcohol or drug abuse/dependence in the 3 months prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01625546

Contacts
Contact: Charles L. Raison, MD (520) 314-7492 craison@email.arizona.edu

Locations
United States, Arizona
University of Arizona Recruiting
Tucson, Arizona, United States, 85724
Contact: Kim Kelly, MPA    520-621-0181    kkelly4@email.arizona.edu   
Contact: Angelica Medrano, BA    (520) 626-1737    ahernandez@psychiatry.arizona.edu   
Principal Investigator: Charles L Raison, MD         
Sponsors and Collaborators
University of Arizona
Dr. med. h.c. Erwin Braun Foundation
The Depressive and Bipolar Disorder Alternative Treatment Foundation
Brain & Behavior Research Foundation
Investigators
Principal Investigator: Charles L. Raison, MD University of Arizona
  More Information

Publications:
Responsible Party: University of Arizona
ClinicalTrials.gov Identifier: NCT01625546     History of Changes
Other Study ID Numbers: 12-0147-01
Study First Received: June 19, 2012
Last Updated: February 4, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Arizona:
Major Depressive Disorder
Whole Body Hyperthermia

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Fever
Behavioral Symptoms
Mood Disorders
Mental Disorders
Body Temperature Changes
Signs and Symptoms

ClinicalTrials.gov processed this record on October 19, 2014